|
|
Article: FDA Approves COZAAR as the First and Only Hypertension Medicine to Help Prevent Stroke in Patients with Hypertension and Left Ventricular Hypertrophy.
- Article from:
- Business Wire
- Article date:
- March 25, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--March 25, 2003
In the landmark LIFE trial, once daily COZAAR significantly
reduced the risk of stroke
Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved another new indication for Merck's antihypertensive drug COZAAR(R) (losartan potassium tablets).
The new label states that COZAAR is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (LVH), but there is evidence that this benefit does not apply to black patients. LVH, a thickening of the heart's main ...